Wall Street expects IDEXX Laboratories to report Q2 2026 revenue of $1.20 billion and earnings per share of $3.95, while the stock currently trades around $559.07, nearly 21% below the average analyst price target of $709.00.
Investors are primarily focused on the organic growth of Companion Animal Group (CAG) Diagnostics recurring revenue, with a specific focus on whether the company can hit its 8.5% to 10.5% growth target for the quarter.
This performance is largely dependent on the commercial execution of the inVue Dx analyzer rollout and the adoption of the new Cancer Dx screening platform across veterinary practices. Markets are also looking for signs of stabilization in global veterinary clinical visit volumes to sustain long-term diagnostics demand.